Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.

With the introduction of highly effective and safe therapies with next-generation direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection remains the only treatable chronic infectious disease. The review aims to provide an overview of the therapy revolution with a description of specific DAAs, their mechanisms of action, a summary of the safety and efficacy of specific regimens, and a discussion of populations requiring special therapeutic approaches. DAAs are highly effective, safe, and easy to use. However, challenges such as access to health services and loss of patients from the cascade of care, especially in groups disproportionately affected by HCV infection, such as substance abusers, make it difficult to achieve the WHO's goal of HCV elimination. The proposed strategy to combat these difficulties involves a one-step approach to diagnosing and treating the infection, the availability of long-lasting forms of medication, and the development of an effective vaccine. The aforementioned opportunities are all the more important as the world is facing an opioid epidemic that is translating into an increase in HCV prevalence. This phenomenon is of greatest concern in women of childbearing age and in those already pregnant due to treatment limitations.

Citation

Krystyna Dobrowolska, Michał Brzdęk, Piotr Rzymski, Robert Flisiak, Małgorzata Pawłowska, Jakub Janczura, Kinga Brzdęk, Dorota Zarębska-Michaluk. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals. Expert opinion on pharmacotherapy. 2024 May;25(7):833-852

Mesh Tags

Substances

PMID: 38768013

search → result